CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

Group 1 - CytomX Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference in London on November 20, 2025, at 9:00 a.m. GMT [1] - A live webcast of the presentation will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2] Group 2 - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics for cancer treatment [3] - The company’s PROBODY therapeutic platform aims to create safer and more effective therapies localized to the tumor microenvironment [3] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CytomX has established collaborations with major oncology leaders such as Amgen, Astellas, and Bristol Myers Squibb [3]